Cannabinoid type 2 receptor activation inhibits MPP
Humans
Microglia
/ metabolism
Proto-Oncogene Proteins c-akt
/ metabolism
Phosphatidylinositol 3-Kinases
/ metabolism
NF-E2-Related Factor 2
/ metabolism
1-Methyl-4-phenylpyridinium
/ pharmacology
Phosphatidylinositol 3-Kinase
/ metabolism
Neuroinflammatory Diseases
Receptor, Cannabinoid, CB2
/ genetics
Signal Transduction
Cannabinoids
/ pharmacology
Cannabinoid type 2 receptor
JWH133
M1/M2 transformation
Microglia
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
29
10
2022
accepted:
17
03
2023
medline:
1
5
2023
pubmed:
29
3
2023
entrez:
28
3
2023
Statut:
ppublish
Résumé
Growing evidence indicates that cannabinoid type 2 (CB2) receptor activation inhibits neuroinflammation in the pathogenesis of Parkinson's disease (PD). Nonetheless, the precise mechanisms of CB2 receptor-mediated neuroprotection have not been fully elucidated. The differentiation of microglia from the M1 to M2 phenotype plays a vital role in neuroinflammation. In the present study, we investigated the effect of CB2 receptor activation on the M1/M2 phenotypic transformation of microglia treated with 1-methyl-4-phenylpyridinium (MPP+). The M1 phenotype microglia markers, including inducible nitric oxide (iNOS), interleukin 6 (IL-6), and CD86, and the M2 phenotype microglia markers, including arginase-1 (Arg-1), IL-10, and CD206, were detected by western blots and flow cytometry. The levels of phosphoinositide-3-kinase (PI3K)/Akt and nuclear factor erythroid 2-related factor 2 (Nrf2) were determined by Western blots. Subsequent addition of Nrf2 inhibitors initially revealed the specific mechanism by which CB2 receptors affect phenotypic changes in microglia. Our results showed that pretreatment with JWH133 significantly inhibited the MPP The results indicate that CB2 receptor activation promotes MPP
Sections du résumé
BACKGROUND
BACKGROUND
Growing evidence indicates that cannabinoid type 2 (CB2) receptor activation inhibits neuroinflammation in the pathogenesis of Parkinson's disease (PD). Nonetheless, the precise mechanisms of CB2 receptor-mediated neuroprotection have not been fully elucidated. The differentiation of microglia from the M1 to M2 phenotype plays a vital role in neuroinflammation.
METHODS
METHODS
In the present study, we investigated the effect of CB2 receptor activation on the M1/M2 phenotypic transformation of microglia treated with 1-methyl-4-phenylpyridinium (MPP+). The M1 phenotype microglia markers, including inducible nitric oxide (iNOS), interleukin 6 (IL-6), and CD86, and the M2 phenotype microglia markers, including arginase-1 (Arg-1), IL-10, and CD206, were detected by western blots and flow cytometry. The levels of phosphoinositide-3-kinase (PI3K)/Akt and nuclear factor erythroid 2-related factor 2 (Nrf2) were determined by Western blots. Subsequent addition of Nrf2 inhibitors initially revealed the specific mechanism by which CB2 receptors affect phenotypic changes in microglia.
RESULTS
RESULTS
Our results showed that pretreatment with JWH133 significantly inhibited the MPP
CONCLUSION
CONCLUSIONS
The results indicate that CB2 receptor activation promotes MPP
Identifiants
pubmed: 36977807
doi: 10.1007/s11033-023-08395-4
pii: 10.1007/s11033-023-08395-4
doi:
Substances chimiques
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
1,1-dimethylbutyl-1-deoxy-Delta(9)-THC
TDG8048RDA
Phosphatidylinositol 3-Kinases
EC 2.7.1.-
NF-E2-Related Factor 2
0
1-Methyl-4-phenylpyridinium
R865A5OY8J
Phosphatidylinositol 3-Kinase
EC 2.7.1.137
Receptor, Cannabinoid, CB2
0
Cannabinoids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4423-4433Subventions
Organisme : Key Technology Research and Development Program of Shandong
ID : No. 2019GSF108095
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Forno LS (1996) Neuropathology of Parkinson’s disease. J Neuropathol Exp Neurol 55:259–272
doi: 10.1097/00005072-199603000-00001
pubmed: 8786384
Skaper SD, Giusti P, Facci L (2012) Microglia and mast cells: two tracks on the road to neuroinflammation. FASEB J 26:3103–3117
doi: 10.1096/fj.11-197194
pubmed: 22516295
Kam TI, Hinkle JT, Dawson TM, Dawson VL (2020) Microglia and astrocyte dysfunction in Parkinson’s disease. Neurobiol Dis 144:105028
doi: 10.1016/j.nbd.2020.105028
pmcid: 7484088
pubmed: 32736085
Sugama S, Takenouchi T, Cho BP, Joh TH, Hashimoto M, Kitani H (2009) Possible roles of microglial cells for neurotoxicity in clinical neurodegenerative diseases and experimental animal models. Inflamm Allergy Drug Targets 8:277–284
doi: 10.2174/187152809789352249
pubmed: 19754411
Martinez FO, Gordon S (2014) The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep 6:13
doi: 10.12703/P6-13
pmcid: 3944738
pubmed: 24669294
Cassano T, Calcagnini S, Pace L, De Marco F, Romano A, Gaetani S (2017) Cannabinoid receptor 2 signaling in neurodegenerative Disorders: from pathogenesis to a Promising Therapeutic Target. Front Neurosci 11:30
doi: 10.3389/fnins.2017.00030
pmcid: 5288380
pubmed: 28210207
Lisboa SF, Gomes FV, Guimaraes FS, Campos AC (2016) Microglial cells as a link between Cannabinoids and the Immune Hypothesis of Psychiatric Disorders. Front Neurol 7:5
doi: 10.3389/fneur.2016.00005
pmcid: 4729885
pubmed: 26858686
Tao Y, Li L, Jiang B, Feng Z, Yang L, Tang J, Chen Q, Zhang J, Tan Q, Feng H, Chen Z, Zhu G (2016) Cannabinoid receptor-2 stimulation suppresses neuroinflammation by regulating microglial M1/M2 polarization through the cAMP/PKA pathway in an experimental GMH rat model. Brain Behav Immun 58:118–129
doi: 10.1016/j.bbi.2016.05.020
pubmed: 27261088
Zhao Y, Zhang Q, Xi J, Xiao B, Li Y, Ma C (2015) Neuroprotective effect of fasudil on inflammation through PI3K/Akt and Wnt/beta-catenin dependent pathways in a mice model of Parkinson’s disease. Int J Clin Exp Pathol 8:2354–2364
pmcid: 4440051
pubmed: 26045742
Galan-Ganga M, Del Rio R, Jimenez-Moreno N, Diaz-Guerra M, Lastres-Becker I (2020) Cannabinoid CB2 receptor modulation by the transcription factor NRF2 is specific in Microglial cells. Cell Mol Neurobiol 40:167–177
doi: 10.1007/s10571-019-00719-y
pubmed: 31385133
de Oliveira MR, Ferreira GC, Schuck PF (2016) Protective effect of carnosic acid against paraquat-induced redox impairment and mitochondrial dysfunction in SH-SY5Y cells: role for PI3K/Akt/Nrf2 pathway. Toxicol In Vitro 32:41–54
doi: 10.1016/j.tiv.2015.12.005
pubmed: 26686574
Wu Q, Ma Y, Liu Y, Wang N, Zhao X, Wen D (2020) CB2R agonist JWH-133 attenuates chronic inflammation by restraining M1 macrophage polarization via Nrf2/HO-1 pathway in diet-induced obese mice. Life Sci 260:118424
doi: 10.1016/j.lfs.2020.118424
pubmed: 32949586
Popiolek-Barczyk K, Rojewska E, Jurga AM, Makuch W, Zador F, Borsodi A, Piotrowska A, Przewlocka B, Mika J (2014) Minocycline enhances the effectiveness of nociceptin/orphanin FQ during neuropathic pain. Biomed Res Int 2014:762930
doi: 10.1155/2014/762930
pmcid: 4168034
pubmed: 25276817
Zhao S, Wang M, Ma Z (2021) Therapeutic potential of ATP-sensitive potassium channels in Parkinson’s disease. Brain Res Bull 169:1–7
doi: 10.1016/j.brainresbull.2021.01.003
pubmed: 33434622
More SV, Kumar H, Kim IS, Song SY, Choi DK (2013) Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson’s disease, Mediators Inflamm, Doi 10.1155/2013/952375
doi: 10.1155/2013/952375
Lu Y, Zhou M, Li Y, Li Y, Hua Y, Fan Y (2021) Minocycline promotes functional recovery in ischemic stroke by modulating microglia polarization through STAT1/STAT6 pathways. Biochem Pharmacol 186:114464
doi: 10.1016/j.bcp.2021.114464
pubmed: 33577892
Du RH, Sun HB, Hu ZL, Lu M, Ding JH, Hu G (2018) Kir6.1/K-ATP channel modulates microglia phenotypes: implication in Parkinson’s disease. Cell Death Dis 9:404
doi: 10.1038/s41419-018-0437-9
pmcid: 5852118
pubmed: 29540778
Castillo PE, Younts TJ, Chavez AE, Hashimotodani Y (2012) Endocannabinoid signaling and synaptic function. Neuron 76:70–81
doi: 10.1016/j.neuron.2012.09.020
pmcid: 3517813
pubmed: 23040807
Javed H, Azimullah S, Haque ME, Ojha SK (2016) Cannabinoid type 2 (CB2) receptors activation protects against oxidative stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson’s Disease. Front Neurosci 10:321
doi: 10.3389/fnins.2016.00321
pmcid: 4969295
pubmed: 27531971
Gubellini P, Kachidian P (2015) Animal models of Parkinson’s disease: an updated overview. Rev Neurol (Paris) 171:750–761
doi: 10.1016/j.neurol.2015.07.011
pubmed: 26343921
He Q, Wang Q, Yuan C, Wang Y (2017) Downregulation of mir-7116-5p in microglia by MPP(+) sensitizes TNF-alpha production to induce dopaminergic neuron damage. Glia 65:1251–1263
doi: 10.1002/glia.23153
pubmed: 28543680
Huang H, Gao Y, Nie K, Wang L (2021) [Macrophage migration inhibitory factor meditates MPP+/MPTP-induced NLRP3 inflammasome activation in microglia cells]. Nan Fang Yi Ke Da Xue Xue Bao 41:972–979
pubmed: 34308845
Zhou P, Weng R, Chen Z, Wang R, Zou J, Liu X, Liao J, Wang Y, Xia Y, Wang Q (2016) TLR4 Signaling in MPP(+)-Induced Activation of BV-2 Cells, Neural Plast https://doi.org/10.1155/2016/5076740
doi: 10.1155/2016/5076740
pmcid: 5215640
pubmed: 28101381
Ma L, Jia J, Liu X, Bai F, Wang Q, Xiong L (2015) Activation of murine microglial N9 cells is attenuated through cannabinoid receptor CB2 signaling. Biochem Biophys Res Commun 458:92–97
doi: 10.1016/j.bbrc.2015.01.073
pubmed: 25637536
Dong W, Luo B, Qiu C, Jiang X, Shen B, Zhang L, Liu W, Zhang W (2020) TRIM3 attenuates apoptosis in Parkinson’s disease via activating PI3K/AKT signal pathway. Aging 13:735–749
doi: 10.18632/aging.202181
pmcid: 7835008
pubmed: 33253119
Li J, Cheng X, Fu D, Liang Y, Chen C, Deng W, He L (2022) Autophagy of spinal Microglia affects the activation of Microglia through the PI3K/AKT/mTOR signaling pathway. Neuroscience 482:77–86
doi: 10.1016/j.neuroscience.2021.12.005
pubmed: 34902496
Zhong Y, Cai X, Ding L, Liao J, Liu X, Huang Y, Chen X, Long L (2022) Nrf2 inhibits the progression of Parkinson’s disease by upregulating AABR07032261.5 to repress pyroptosis. J Inflamm Res 15:669–685
doi: 10.2147/JIR.S345895
pmcid: 8818975
pubmed: 35140498
Subedi L, Lee JH, Yumnam S, Ji E, Kim SY (2019) Anti-inflammatory effect of sulforaphane on LPS-Activated Microglia potentially through JNK/AP-1/NF-kappaB inhibition and Nrf2/HO-1 activation, Cells 8(2): 194
doi: 10.3390/cells8020194
pmcid: 6406309
pubmed: 30813369
Liao S, Wu J, Liu R, Wang S, Luo J, Yang Y, Qin Y, Li T, Zheng X, Song J, Zhao X, Xiao C, Zhang Y, Bian L, Jia P, Bai Y, Zheng X (2020) A novel compound DBZ ameliorates neuroinflammation in LPS-stimulated microglia and ischemic stroke rats: role of akt(Ser473)/GSK3beta(Ser9)-mediated Nrf2 activation. Redox Biol 36:101644
doi: 10.1016/j.redox.2020.101644
pmcid: 7371982
pubmed: 32863210
Wang N, Nie H, Zhang Y, Han H, Wang S, Liu W, Tian K (2022) Dexmedetomidine exerts cerebral protective effects against cerebral ischemic injury by promoting the polarization of M2 microglia via the Nrf2/HO-1/NLRP3 pathway. Inflamm Res 71:93–106
doi: 10.1007/s00011-021-01515-5
pubmed: 34767031